Tildrakizumab Approval Status
- FDA approved: No
- Generic name: tildrakizumab
- Company: Sun Pharmaceutical Industries Inc.
- Treatment for: Plaque Psoriasis
Tildrakizumab is an investigational humanized, anti-IL-23p19 monoclonal antibody in development for the treatment of moderate-to-severe plaque psoriasis.
Development Status and FDA Approval Process for tildrakizumab
| Date | Article |
|---|---|
| May 24, 2017 | Sun Pharma Announces US FDA Filing Acceptance of Biologics License Application (BLA) For Tildrakizumab |
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.
